

FIG. 1






FIG. 1



Patient (1) - P1



Patient (2) - P1

FIG. 2




FIG. 3




FIG. 4

5/22

Patient(1)-P2




FIG. 5

6/22




FIG. 6




FIG. 7

8/22




FIG. 8

9/22




FIG. 9

10/22




FIG. 10




FIG. 11

12/22




FIG. 12

**Use of B38.1 antibody to direct
the infection of adenovirus to tumorigenic breast cancer cells**




**All cells tumorigenic
Targeting tumor**



**Breast cancer stem cells
Targeting subpopulation of cells**

FIG. 13

Cross-linking method to generate bi-specific antibodies



SHA2-Anti-Fiber

PDBA-Anti-B38.1



Bi-specific antibody

FIG. 14

Targeting adenoviral infection to B38.1+ cells




FIG. 15

Targeting adenovirus infection to breast cancer cells




FIG. 16

Targeting of Adenovirus to different human cell lines










FIG. 17

Specific targeting of adenovirus
to breast cancer cells expressing B38.1

MCF7
(B38.1+)



HeLa
(B38.1-)



Control

α -Fiber

α -Fiber+B38.1

FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22